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Antibodies specific for self-antigens mediate life-
threatening pathology in several autoimmune diseases.
Clearly the ability to target the plasma cells (PCs)
producing the autoantibodies would be of great
clinical benefit. Current immunosuppressive thera-
pies are based on the premise that autoreactive PCs
are short-lived and replenished from ongoing immune
responses. However, recent results question this as-
sumption and suggest that optimizing the treatment
of severe autoimmune conditions will require a sig-
nificant investment in elucidating the details of PC
biology.
 
Conventional therapy for autoimmune conditions in
which the symptoms are mediated by antibody—such as
systemic lupus erythematosus (SLE)—depends on the severity
of the symptoms and the circumstances of the patient. In
general, mild forms of disease are first treated with steroidal
and nonsteroidal antiinflammatories. More severe forms,
involving organ dysfunction due to active disease, usually
are treated with steroids in conjunction with strong immu-
nosuppressive agents such as cyclophosphamide, a cytotoxic
agent that targets cycling cells. Such stringent therapy is
applied for the period required to induce remission. This
treatment regime has been very successful in managing
autoimmune diseases such as SLE with, in one study, 25%
of patients achieving at least one remission of at least 1 yr
duration (1). Not all patients respond to cyclophosphamide,
and among these nonresponders novel therapies including
B cell depletion are being tried with varying levels of success
(2). The success of treating antibody-mediated disease by
immunosuppression based on killing cycling cells fits well
with a dogma developed during the 1980’s that held PCs to
be short-lived and produced continuously from cycling
precursors (3). Although it may well be that a significant
fraction of the PC-secreting autoantibodies in SLE fit this
category and are therefore sensitive to current therapeutic
approaches, patients may to varying degrees harbor autore-
active PCs that are long-lived and sessile. The presence and
frequency of long-lived, disease-associated PCs may turn
out to be an important indicator of therapeutic success,
providing information on the likelihood of entering and
remaining in remission.
Although the generation of long-lived PCs in response
to foreign antigens was conclusively shown some time ago
(4, 5), the first clear demonstration that such cells are pro-
duced during an autoimmune response is provided in the
article of Hoyer et al. in this issue (pages 1577–1584) (6).
They show in a mouse model of SLE that a large frac-
tion of the PC-producing anti–self-antibodies (anti-DNA
in this case) are long-lived, sessile cells in the bone marrow
that withstand treatment with cyclophosphamide. These
findings imply that developing therapies that control autoanti-
body production will require a detailed knowledge of the
PC populations involved in the particular disease. Is the PC
short- or long-lived; is it derived from cycling or quiescent
precursors; where is it located; is its survival intrinsic or
dependent on its environment? To identify points and
methods of clinical intervention, it will first be necessary to
elucidate a developmental scheme for PCs and then define
variations unique to particular diseases. Here we outline
our current understanding of plasma cell development and
the parts of the puzzle that are missing.
 
PC Development in All Its (Current) Glory.
 
Antibody-
secreting cells were at one point divided into two catego-
ries: the plasmablast and the more mature PCs (7). The PC
compartment has been further divided into short- and long-
lived cells (4, 5, 8), with the latter being considered more
mature. Within such a simple scheme, however, precursor–
product relationships have been difficult to define. For
example, the plasmablasts that appear within the foci in the
extrafollicular areas of lymphoid tissues shortly after immu-
nization (9) have a limited lifespan and are considered to die
in situ (10). It is unknown whether plasmablasts give rise to
short- or long-lived PCs (11). Antibody production continues
well after the loss of the extrafollicular foci due to PCs located
in the splenic red pulp, for example, and in bone marrow
(12, 13). Despite knowing for some time that plasma cells
with varying life-span exist in these locations (8), it remains
unclear whether one (long) is derived from the other
(short). In addition to longer lifespan, PC maturation is con-
sidered to involve changes in phenotype. Certain PCs do
not express MHC class II, CD19, and CD45 (10, 14), and
in general loss of B cell differentiation markers correlates
with increased lifespan and is considered a sign of maturity.
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However, it is not clear if the phenotypic changes represent
distinct stages in a linear progression or are to some extent
stochastic (15). In mice, PCs from all defined subsets have
been shown to express CD138 (16) (although not all PCs
are necessarily CD138
 
 
 
 nor are all CD138
 
 
 
 cells PC [17])
making it something of a beacon in PC biology as it is
almost the only marker that allows the prospective identi-
fication of PCs rather than retrospectively measuring im-
munoglobulin secretion. In humans, CD138 expression is
restricted to PC of the bone marrow (18), and CD38 ex-
pression provides a somewhat less robust alternative marker
(19). Collectively, ample heterogeneity has been identified
among PCs to satisfy the most ardent immunological sub-
setter, but it has yet to allow the construction of a develop-
mental scheme whereby a particular phenotype can be asso-
ciated with a particular function, lifespan, or fate. Added to
this complexity is the fact that in autoimmune diseases im-
mune reactions occurring outside lymphoid tissues (20) and
PC accumulating in inflamed tissues (21) will contribute to
antibody production. Both conditions may confer distinct
properties on the PCs they produce.
 
PC Precursors: It Never Rains, It Pours.
 
Next is the ques-
tion of the cellular origin of PCs. Are particular PC pheno-
types or the PCs found in particular locations associated
with distinct cellular origins? Such relationships may deter-
mine the pathogenicity of the antibodies being produced.
For example, PCs derived from germinal centers (GCs)
may secrete antibody of a mature (IgG) isotype and of high
affinity for antigen, both factors that may exacerbate tissue
damage. Thus, knowing the etiology of a PC may identify
points and means of clinical intervention. There are several
developmental schemes for PCs that collectively encompass
virtually every possible connection (Fig. 1). Although plas-
mablasts are potential PC precursors of long standing (7),
several other populations have joined them recently. The
GC is broadly accepted to produce PCs that are high affin-
ity, long-lived, and that reside primarily in the bone mar-
row (13, 22). Defining the developmental processes that
drive a GC B cell toward becoming a long-lived bone mar-
row PC may identify points at which the development of
pathogenic autoantibodies can be interrupted, assuming
that the long-lived PC-secreting pathogenic autoantibodies
in the bone marrow are GC derived, which may not al-
ways be the case (23). If, for example, the process of PC
differentiation depends on antigen-induced signaling (24),
the creation of environmental niches (25), and chemokine
gradients (26), then modulating any of these may be suffi-
cient to modulate disease severity. One must include also
the traditional memory B cell population as containing PC
precursors since such cells rapidly differentiate into short-
lived PC upon reexposure to antigen (27, 28). In mouse,
two additional precursor populations have been identified:
both B220
 
 
 
 and both concentrated in the bone marrow.
One of these is cycling (29) and therefore presumably sus-
ceptible to the treatment applied by Hoyer et al. (6) that
failed to block anti-DNA antibody production. The role of
this population in the maintenance of long-lived autoreac-
tive PCs in the bone marrow therefore remains open. The
other B220
 
 
 
 population is derived from the GCs, lacks ex-
pression of CD138, is developmentally dependent on a
transcriptional regulator of PC development, Blimp1 (30,
31), and is responsive to antigen, which long-lived PCs are
not (14). Again, the role of this population in the mainte-
nance of long-lived PCs is unresolved. In humans, PC pre-
cursor diversity is less well defined, although stages of mat-
uration have been identified in blood ranging from a
plasma cell precursor (32) to more discrete stages within
committed PC (33, 34). Interestingly, one of these studies
noted a significant increase in plasma cell precursor fre-
quency in the blood of children with SLE (32), which
complements other studies reporting a correlation between
disease activity and circulating PCs (35). These data raise
the possibility that aspects of the immune response are dys-
functional in these patients, and if the developmental origin
of the PC were known, it may be possible to intervene in a
relatively precise manner. The definition of relationships
between precursors and PCs is going to be crucial if selec-
tive therapies are to be developed that target only the rele-
vant PC subset.
 
Solving the Problem of PC Development.
 
Immunologists
are nothing if not adept at defining developmental path-
ways. What is required to elucidate PC development is rel-
atively simple to write but more complicated to effect. First
is the efficient identification of the earliest B cell commit-
ted to becoming a PC, thereby allowing its isolation and
manipulation. Currently PC identification relies on the en-
richment provided by various fortuitously identified mark-
ers such as CD138. Although this certainly helps, it results
in considerable heterogeneity in the recovered popula-
tion. The identification of early stages of PC development
would allow the developmental potential and differentia-
tion requirements of such cells to be defined in vitro and in
vivo. This would allow also for the rapid accumulation of
additional markers in a developmentally ordered manner,
creating the schemes that have been so useful in the analysis
of white blood cell development. Second is the exploita-
Figure 1. The tangled web of PCs and their precursors. Schematic rep-
resentation of PC subsets and their postulated or proven precursors and
products. SL, short-lived; LL, long-lived; Ag, antigen. 
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tion of in vitro systems to define the impact of various fac-
tors that affect PC production. Small changes in respon-
siveness to differentiation stimuli such as the cytokines IL-5
and IL-10 can, over the course of an immune response,
culminate in huge differences in the size and composition
of the effector populations generated (15).
 
Implications for Treating Autoimmune Diseases
 
Appropri-
ate and targeted therapy of antibody-mediated autoim-
mune diseases, as highlighted by Hoyer et al. (6), is going
to depend on identifying the PCs involved in a disease pro-
cess and targeting the critical component(s) of its develop-
ment, be that the cycling precursor, the stimuli driving its
proliferation, the factors promoting its maturation, or ele-
ments of its survival niche, both stromal and soluble. Po-
tential approaches include: the cytotoxic and antiinflamma-
tory drugs already in use; inhibiting B–T cell interactions
(36); blocking factors that promote PC maturation, such as
BAFF/BlyS (37); interfering with chemotaxis (38); and
blocking the interaction between PC and stromal elements,
such as adhesion molecules and cytokines (39).
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